FDA approves Ironwood’s Linzess for young children With constipation
Ironwood Pharmaceuticals (NASDAQ:IRWD) secured expanded U.S. regulatory clearance for its blockbuster drug Linzess, making it the first and only prescription medication available for young children suffering from functional constipation.


_1407809_640x360_2501513283798-640x360.webp&w=3840&q=75)
_1407802_640x360_2501517891866-640x360.webp&w=3840&q=75)


_1407766_640x360_2501510723947-640x360.webp&w=3840&q=75)
_1407763_640x360_2501515331638-640x360.webp&w=3840&q=75)
_1407744_640x360_2501515331575-640x360.webp&w=3840&q=75)
_1407728_640x360_2501511747998-640x360.webp&w=3840&q=75)

